Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist: Part II: Management of stage IV disease

Journal of the American Academy of Dermatology

Volumn 68, Issue 1, 2013, Pages 13.e1-13.e13

  Fox, Matthew C ^a   Lao, Christopher D ^a   Schwartz, Jennifer L ^a   Frohm, Marcus L ^a   Bichakjian, Christopher K ^a   Johnson, Timothy M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

dacarbazine; distress thermometer; interleukin 2; ipilimumab; melanoma; vemurafenib

Indexed keywords

BMS 936559; CARBOPLATIN; CISPLATIN; DABRAFENIB; DACARBAZINE; GLYCOPROTEIN GP 100 PEPTIDE VACCINE; IMATINIB; IPILIMUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PEPTIDE VACCINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; VINBLASTINE;

ANOREXIA; ARTHRALGIA; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CAPILLARY LEAK SYNDROME; CONSTIPATION; DARIER DISEASE; DERMATOLOGIST; DIARRHEA; DRUG COST; DRUG CYTOTOXICITY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EDEMA; ERYTHRODERMA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEPATORENAL SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; HYPOTHYROIDISM; INFLAMMATION; KERATOACANTHOMA; LIVER DISEASE; METASTATIC MELANOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEBORRHEIC DERMATITIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; VITILIGO;

EID: 84870878674     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.09.041     Document Type: Review

References (80)

1. A. Barth, L.A. Wanek, and D.L. Morton Prognostic factors in 1,521 melanoma patients with distant metastases J Am Coll Surg 181 1995 193 201
2. C.K. Bichakjian, A.C. Halpern, T.M. Johnson, A. Foote Hood, J.M. Grichnik, and S.M. Swetter Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology J Am Acad Dermatol 65 2011 1032 1047
3. D.G. Coit, R. Andtbacka, C.J. Anker, C.K. Bichakjian, R. Carson 3rd, and A. Daud Melanoma J Natl Compr Canc Netw 10 2012 366 400
4. M.L. Alegre, K.A. Frauwirth, and C.B. Thompson T-cell regulation by CD28 and CTLA-4 Nat Rev Immunol 1 2001 220 228
5. M.C. Brunner, C.A. Chambers, F.K. Chan, J. Hanke, A. Winoto, and J.P. Allison CTLA-4-mediated inhibition of early events of T cell proliferation J Immunol 162 1999 5813 5820
6. R.J. Greenwald, M.A. Oosterwegel, D. van der Woude, A. Kubal, D.A. Mandelbrot, and V.A. Boussiotis CTLA-4 regulates cell cycle progression during a primary immune response Eur J Immunol 32 2002 366 373
7. S.F. Ibrahim, D. Sambandan, and D. Ratner Immunotherapy for cutaneous malignancy Dermatol Surg 37 2011 1377 1393
8. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
9. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, and Garbe C. M DJ Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
10. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
11. A.M. Menzies, L. Visintin, M.D. Chatfield, M.S. Carlino, J.R. Howle, and R.A. Scolyer BRAF mutation by age-decade and body mass index in metastatic melanoma (abstract) J Clin Oncol 29 suppl 2011 8507
12. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
13. A. Ribas, and K.T. Flaherty BRAF targeted therapy changes the treatment paradigm in melanoma Nat Rev Clin Oncol 8 2011 426 433
14. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
15. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, and J.S. Weber Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
16. S. Bhatia, and J.A. Thompson Systemic therapy for metastatic melanoma in 2012: dawn of a new era J Natl Compr Canc Netw 10 2012 403 412
17. I.V. Fedorenko, K.H. Paraiso, and K.S. Smalley Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma Biochem Pharmacol 82 2011 201 209
18. J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, and A.K. Cipolla Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
19. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, and H. Lee Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
20. N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, and P. Pochanard Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 29 2011 3085 3096
21. M.B. Atkins, M.T. Lotze, J.P. Dutcher, R.I. Fisher, G. Weiss, and K. Margolin High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105 2116
22. G.Q. Phan, P. Attia, S.M. Steinberg, D.E. White, and S.A. Rosenberg Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma J Clin Oncol 19 2001 3477 3482
23. M.B. Atkins, L. Kunkel, M. Sznol, and S.A. Rosenberg High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update Cancer J Sci Am 6 suppl 1 2000 S11 S14
24. S.M. Lee, D.C. Betticher, and N. Thatcher Melanoma: chemotherapy Br Med Bull 51 1995 609 630
25. M.R. Middleton, J.J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, and S. Seiter Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 2000 158 166
26. A.S. Yang, and P.B. Chapman The history and future of chemotherapy for melanoma Hematol Oncol Clin North Am 23 2009 583 597
27. P.B. Chapman, L.H. Einhorn, M.L. Meyers, S. Saxman, A.N. Destro, and K.S. Panageas Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma J Clin Oncol 17 1999 2745 2751
28. L. Serrone, M. Zeuli, F.M. Sega, and F. Cognetti Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview J Exp Clin Cancer Res 19 2000 21 34
29. T.M. Johnson, R.P. Rapini, and M. Duvic Inflammation of actinic keratoses from systemic chemotherapy J Am Acad Dermatol 17 1987 192 197
30. I. Quirt, S. Verma, T. Petrella, K. Bak, and M. Charette Temozolomide for the treatment of metastatic melanoma: a systematic review Oncologist 12 2007 1114 1123
31. P.H. Wiernik, and A.I. Einzig Taxol in malignant melanoma J Natl Cancer Inst Monogr 1993 185 187
32. N.E. Papadopoulos, A. Bedikian, S. Ring, K.B. Kim, W.J. Hwu, and D.L. Gerber Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma Am J Clin Oncol 32 2009 509 514
33. R.D. Rao, S.G. Holtan, J.N. Ingle, G.A. Croghan, L.A. Kottschade, and E.T. Creagan Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma Cancer 106 2006 375 382
34. A. Hauschild, S.S. Agarwala, U. Trefzer, D. Hogg, C. Robert, and P. Hersey Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 27 2009 2823 2830
35. S.S. Legha, S. Ring, O. Eton, A. Bedikian, A.C. Buzaid, and C. Plager Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma J Clin Oncol 16 1998 1752 1759
36. O. Eton, S.S. Legha, A.Y. Bedikian, J.J. Lee, A.C. Buzaid, and C. Hodges Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial J Clin Oncol 20 2002 2045 2052
37. N.J. Ives, R.L. Stowe, P. Lorigan, and K. Wheatley Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-Analysis of 18 trials involving 2,621 patients J Clin Oncol 25 2007 5426 5434
38. M.B. Atkins, J. Hsu, S. Lee, G.I. Cohen, L.E. Flaherty, and J.A. Sosman Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 26 2008 5748 5754
39. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 2006 4340 4346
40. R.D. Carvajal, C.R. Antonescu, J.D. Wolchok, P.B. Chapman, R.A. Roman, and J. Teitcher KIT as a therapeutic target in metastatic melanoma JAMA 305 2011 2327 2334
41. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, and P.J. Roberts Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
42. F.S. Hodi, P. Friedlander, C.L. Corless, M.C. Heinrich, S. Mac Rae, and A. Kruse Major response to imatinib mesylate in KIT-mutated melanoma J Clin Oncol 26 2008 2046 2051
43. J. Lutzky, J. Bauer, and B.C. Bastian Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation Pigment Cell Melanoma Res 21 2008 492 493
44. I. Satzger, U. Kuttler, B. Volker, F. Schenck, A. Kapp, and R. Gutzmer Anal mucosal melanoma with KIT-Activating mutation and response to imatinib therapy - case report and review of the literature Dermatology 220 2010 77 81
45. J. Guo, L. Si, Y. Kong, K.T. Flaherty, X. Xu, and Y. Zhu Phase II, open-label, single-Arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification J Clin Oncol 29 2011 2904 2909
46. G.S. Falchook, G.V. Long, R. Kurzrock, K.B. Kim, T.H. Arkenau, and M.P. Brown Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet 379 2012 1893 1901
47. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, and P. Hwu Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
48. K.S. Smalley, A.E. Aplin, K.T. Flaherty, C. Hoeller, A.K. Bosserhoff, and N.K. Haass Meeting report from the 2011 International Melanoma Congress, Tampa, Florida Pigment Cell Melanoma Res 25 2012 E1 E11
49. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, and O. Spleiss RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 366 2012 207 215
50. J.S. Weber, K.T. Flaherty, J.R. Infante, G.S. Falchook, R. Kefford, and A. Daud Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma (abstract) J Clin Oncol 30 suppl 2012 8510
51. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, and M. Milhem Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2012 107 114
52. A.C. Halpern Combining forces: vemurafenib and ipilimumab to be tried together The Melanoma Letter 2011 29
53. V. Huang, D. Hepper, M. Anadkat, and L. Cornelius Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway Arch Dermatol 148 2012 628 633
54. J.J. Harding, M. Pulitzer, and P.B. Chapman Vemurafenib sensitivity skin reaction after ipilimumab N Engl J Med 366 2012 866 868
55. A.T. Weeraratna RAF around the edges - the paradox of BRAF inhibitors N Engl J Med 366 2012 271 273
56. R. Anforth, T.C. Blumetti, A. Mohd Affandi, and P. Fernandez-Penas Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib J Clin Oncol 30 2012 e165 e167
57. R.A. Patchell, P.A. Tibbs, J.W. Walsh, R.J. Dempsey, Y. Maruyama, and R.J. Kryscio A randomized trial of surgery in the treatment of single metastases to the brain N Engl J Med 322 1990 494 500
58. C.J. Vecht, H. Haaxma-Reiche, E.M. Noordijk, G.W. Padberg, J.H. Voormolen, and F.H. Hoekstra Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33 1993 583 590
59. A.M. Stark, H. Tscheslog, R. Buhl, J. Held-Feindt, and H.M. Mehdorn Surgical treatment for brain metastases: prognostic factors and survival in 177 patients Neurosurg Rev 28 2005 115 119
60. Nabors LB, AM, Bierman PJ, Brem H, Butowski N, Chamberlain MC, et al. Central nervous system cancers. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. 2012;version 1.2012. Available at http://www.nccn.org/professionals/physician-gls/pdf/cns.pdf. Accessed October 18, 2012.
61. N.M. Rochet, L.A. Kottschade, and S.N. Markovic Vemurafenib for melanoma metastases to the brain N Engl J Med 365 2011 2439 2441
62. K. Margolin, M.S. Ernstoff, O. Hamid, D. Lawrence, D. McDermott, and I. Puzanov Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 13 2012 459 465
63. S. Siena, L. Crino, M. Danova, S. Del Prete, S. Cascinu, and S. Salvagni Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study Ann Oncol 21 2010 655 661
64. J.H. Suh Stereotactic radiosurgery for the management of brain metastases N Engl J Med 362 2010 1119 1127
65. N. Khan, M.K. Khan, A. Almasan, A.D. Singh, and R. Macklis The evolving role of radiation therapy in the management of malignant melanoma Int J Radiat Oncol Biol Phys 80 2011 645 654
66. Y. Mori, D. Kondziolka, J.C. Flickinger, J.M. Kirkwood, S. Agarwala, and L.D. Lunsford Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival Int J Radiat Oncol Biol Phys 42 1998 581 589
67. U. Selek, E.L. Chang, S.J. Hassenbusch 3rd, A.S. Shiu, F.F. Lang, and P. Allen Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases Int J Radiat Oncol Biol Phys 59 2004 1097 1106
68. C. Yu, J.C. Chen, M.L. Apuzzo, S. O'Day, S.L. Giannotta, and J.S. Weber Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery Int J Radiat Oncol Biol Phys 52 2002 1277 1287
69. A.E. Radbill, J.F. Fiveash, E.T. Falkenberg, B.L. Guthrie, P.E. Young, and S. Meleth Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity Cancer 101 2004 825 833
70. M. Scorsetti, A. Facoetti, P. Navarria, M. Bignardi, M. De Santis, and S.A. Ninone Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases Anticancer Res 29 2009 4259 4263
71. S.D. Lavine, Z. Petrovich, A.A. Cohen-Gadol, L.S. Masri, D.L. Morton, and S.J. O'Day Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications Neurosurgery 44 1999 59 64
72. B.P. O'Neill, N.J. Iturria, M.J. Link, B.E. Pollock, K.V. Ballman, and J.R. O'Fallon A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases Int J Radiat Oncol Biol Phys 55 2003 1169 1176
73. D. Rades, J.D. Kueter, T. Veninga, J. Gliemroth, and S.E. Schild Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: results of a matched pair analysis Eur J Cancer 45 2009 400 404
74. A. Schoggl, K. Kitz, M. Reddy, S. Wolfsberger, B. Schneider, and K. Dieckmann Defining the role of stereotactic radiosurgery versus microsurgery in the treatment of single brain metastases Acta Neurochir (Wien) 142 2000 621 626
75. D.W. Andrews, C.B. Scott, P.W. Sperduto, A.E. Flanders, L.E. Gaspar, and M.C. Schell Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial Lancet 363 2004 1665 1672
76. A. Stone, J. Cooper, K.L. Koenig, J.G. Golfinos, and R. Oratz A comparison of survival rates for treatment of melanoma metastatic to the brain Cancer Invest 22 2004 492 497
77. P.C. Trask, A.G. Paterson, S. Hayasaka, R.L. Dunn, M. Riba, and T. Johnson Psychosocial characteristics of individuals with non-stage IV melanoma J Clin Oncol 19 2001 2844 2850
78. J.C. Holland, B. Andersen, W.S. Breitbart, B. Compas, M.M. Dudley, and S. Fleishman Distress management J Natl Compr Canc Netw 8 2010 448 485
79. T.J. Smith, S. Temin, E.R. Alesi, A.P. Abernethy, T.A. Balboni, and E.M. Basch American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care J Clin Oncol 30 2012 880 887
80. J.S. Temel, J.A. Greer, A. Muzikansky, E.R. Gallagher, S. Admane, and V.A. Jackson Early palliative care for patients with metastatic non-small-cell lung cancer N Engl J Med 363 2010 733 742